• 1
    Garboczi DN,Hung DT,Wiley DC. HLA-A2-peptide complexes: Refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc Natl Acad Sci USA 1992; 89: 34293433.
  • 2
    Altman JD,Moss PA,Goulder PJ,Barouch DH,McHeyzer-Williams MG,Bell JI,McMichael AJ,Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274: 9496.
  • 3
    Whelan JA,Dunbar PR,Price DA,Purbhoo MA,Lechner F,Ogg GS,Griffiths G,Phillips RE,Cerundolo V,Sewell AK. Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent. J Immunol 1999; 163: 43424348.
  • 4
    Laugel B,Boulter JM,Lissin N,Vuidepot A,Li Y,Gostick E,Crotty LE,Douek DC,Hemelaar J,Price DA, Jakobsen BK, Sewell AK. Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition. J Biol Chem 2005; 280: 18821892.
  • 5
    Cole DK,Pumphrey NJ,Boulter JM,Sami M,Bell JI,Gostick E,Price DA,Gao GF,Sewell AK,Jakobsen BK. Human TCR-binding affinity is governed by MHC class restriction. J Immunol 2007; 178: 57275734.
  • 6
    Rehr M,Cahenzli J,Haas A,Price DA,Gostick E,Huber M,Karrer U,Oxenius A. Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J Virol 2008; 82: 33913404.
  • 7
    Wolint P,Betts MR,Koup RA,Oxenius A. Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cells. J Exp Med 2004; 199: 925936.
  • 8
    Takata H,Takiguchi M. Three memory subsets of human CD8+ T cells differently expressing three cytolytic effector molecules. J Immunol 2006; 177: 43304340.
  • 9
    Seder RA,Darrah PA,Roederer M. T-cell quality in memory and protection: Implications for vaccine design. Nat Rev Immunol 2008; 8: 247258.
  • 10
    Valitutti S,Muller S,Dessing M,Lanzavecchia A. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med 1996; 183: 19171921.
  • 11
    Price DA,Sewell AK,Dong T,Tan R,Goulder PJ,Rowland-Jones SL,Phillips RE. Antigen-specific release of beta-chemokines by anti-HIV-1 cytotoxic T lymphocytes. Curr Biol 1998; 8: 355358.
  • 12
    Betts MR,Price DA,Brenchley JM,Lore K,Guenaga FJ,Smed-Sorensen A,Ambrozak DR,Migueles SA,Connors M,Roederer M, Douek DC, Koup RA. The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J Immunol 2004; 172: 64076417.
  • 13
    Rubio-Godoy V,Dutoit V,Rimoldi D,Lienard D,Lejeune F,Speiser D,Guillaume P,Cerottini JC,Romero P,Valmori D. Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. Proc Natl Acad Sci USA 2001; 98: 1030210307.
  • 14
    Lyons GE,Roszkowski JJ,Man S,Yee C,Kast WM,Nishimura MI. T-cell receptor tetramerbinding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol Immunother 2006; 55: 11421150.
  • 15
    Laugel B,van den Berg HA,Gostick E,Cole DK,Wooldridge L,Boulter J,Milicic A,Price DA,Sewell AK. Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties. J Biol Chem 2007; 282: 2379923810.
  • 16
    Wooldridge L,Lissina A,Cole DK,van den Berg HA,Price DA,Sewell AK. Tricks with tetramers: How to get the most from multimeric peptide-MHC. Immunology (in press).
  • 17
    Guillaume P,Legler DF,Boucheron N,Doucey MA,Cerottini JC,Luescher IF. Soluble major histocompatibility complex-peptide octamers with impaired CD8 binding selectively induce Fas-dependent apoptosis. J Biol Chem 2003; 278: 45004509.
  • 18
    Roederer M. How many events is enough? Are you positive? Cytometry A 2008; 73: 384385.
  • 19
    Perfetto SP,Chattopadhyay PK,Lamoreaux L,Nguyen R,Ambrozak D,Koup RA,Roederer M. Amine reactive dyes: An effective tool to discriminate live and dead cells in polychromatic flow cytometry. J Immunol Methods 2006; 313: 199208.
  • 20
    Perfetto SP,Chattopadhyay PK,Roederer M. Seventeen-colour flow cytometry: Unravelling the immune system. Nat Rev Immunol 2004; 4: 648655.
  • 21
    Chattopadhyay PK,Price DA,Harper TF,Betts MR,Yu J,Gostick E,Perfetto SP,Goepfert P,Koup RA, De Rosa SC, Bruchez MP, Roederer M. Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry. Nat Med 2006; 12: 972977.
  • 22
    Lee PP,Yee C,Savage PA,Fong L,Brockstedt D,Weber JS,Johnson D,Swetter S,Thompson J,Greenberg PD, Roederer M, Davis MM. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5: 677685.
  • 23
    Zippelius A,Batard P,Rubio-Godoy V,Bioley G,Lienard D,Lejeune F,Rimoldi D,Guillaume P,Meidenbauer N,Mackensen A, Rufer N, Lubenow N, Speiser D, Cerottini JC, Romero P, Pittet MJ. Effector function of human tumor-specific CD8 T cells in melanoma lesions: A state of local functional tolerance. Cancer Res 2004; 64: 28652873.
  • 24
    Wooldridge L,van den Berg HA,Glick M,Gostick E,Laugel B,Hutchinson SL,Milicic A,Brenchley JM,Douek DC,Price DA, Sewell AK. Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. J Biol Chem 2005; 280: 2749127501.
  • 25
    Bodinier M,Peyrat MA,Tournay C,Davodeau F,Romagne F,Bonneville M,Lang F. Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding. Nat Med 2000; 6: 707710.
  • 26
    Purbhoo MA,Boulter JM,Price DA,Vuidepot AL,Hourigan CS,Dunbar PR,Olson K,Dawson SJ,Phillips RE,Jakobsen BK, Bell JI, Sewell AK. The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain. J Biol Chem 2001; 276: 3278632792.
  • 27
    Glick M,Price DA,Vuidepot AL,Andersen TB,Hutchinson SL,Laugel B,Sewell AK,Boulter JM,Dunbar PR,Cerundolo V, Oxenius A, Bell JI, Richards WG, Jakobsen BK. Novel CD8+ T cell antagonists based on beta 2-microglobulin. J Biol Chem 2002; 277: 2084020846.
  • 28
    Price DA,Brenchley JM,Ruff LE,Betts MR,Hill BJ,Roederer M,Koup RA,Migueles SA,Gostick E,Wooldridge L, Sewell AK, Connors M, Douek DC. Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med 2005; 202: 13491361.
  • 29
    Gakamsky DM,Luescher IF,Pramanik A,Kopito RB,Lemonnier F,Vogel H,Rigler R,Pecht I. CD8 kinetically promotes ligand binding to the T-cell antigen receptor. Biophys J 2005; 89: 21212133.
  • 30
    Gao GF,Tormo J,Gerth UC,Wyer JR,McMichael AJ,Stuart DI,Bell JI,Jones EY,Jakobsen BK. Crystal structure of the complex between human CD8alpha(alpha) and HLA-A2. Nature 1997; 387: 630634.
  • 31
    Wyer JR,Willcox BE,Gao GF,Gerth UC,Davis SJ,Bell JI,van der Merwe PA,Jakobsen BK. T cell receptor and coreceptor CD8 alphaalpha bind peptide-MHC independently and with distinct kinetics. Immunity 1999; 10: 219225.
  • 32
    Cole DK,Dunn SM,Sami M,Boulter JM,Jakobsen BK,Sewell AK. T cell receptor engagement of peptide-major histocompatibility complex class I does not modify CD8 binding. Mol Immunol 2008; 45: 27002709.
  • 33
    Pittet MJ,Valmori D,Dunbar PR,Speiser DE,Lienard D,Lejeune F,Fleischhauer K,Cerundolo V,Cerottini JC,Romero P. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999; 190: 705715.
  • 34
    Busch DH,Pamer EG. T cell affinity maturation by selective expansion during infection. J Exp Med 1999; 189: 701710.
  • 35
    Yee C,Savage PA,Lee PP,Davis MM,Greenberg PD. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 1999; 162: 22272234.
  • 36
    Weichsel R,Dix C,Wooldridge L,Clement M,Fenton-May A,Sewell AK,Zezula J,Greiner E,Gostick E,Price DA, Einsele H, Seggewiss R. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008; 14: 24842491.
  • 37
    Lissina A, Ladell K, Skowera A, Clement M, Edwards E, Seggewiss R, van den Berg HA, Gostick E, Gallagher K, Jones E, Godkin AJ, Peakman M, Price DA, Sewell AK, Wooldridge L. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods (in press).
  • 38
    Choi EM,Chen JL,Wooldridge L,Salio M,Lissina A,Lissin N,Hermans IF,Silk JD,Mirza F,Palmowski MJ, Dunbar PR, Jakobsen BK, Sewell AK, Cerundolo V. High avidity antigen-specific CTL identified by CD8-independent tetramer staining. J Immunol 2003; 171: 51165123.
  • 39
    Pittet MJ,Rubio-Godoy V,Bioley G,Guillaume P,Batard P,Speiser D,Luescher I,Cerottini JC,Romero P,Zippelius A. Alpha3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. J Immunol 2003; 171: 18441849.
  • 40
    Gostick E,Cole DK,Hutchinson SL,Wooldridge L,Tafuro S,Laugel B,Lissina A,Oxenius A,Boulter JM,Price DA, Sewell AK. Functional and biophysical characterization of an HLA-A*6801-restricted HIV-specific T cell receptor. Eur J Immunol 2007; 37: 479486.
  • 41
    Wooldridge L,Lissina A,Vernazza J,Gostick E,Laugel B,Hutchinson SL,Mirza F,Dunbar PR,Boulter JM,Glick M, Cerundolo V, van den Berg HA, Price DA, Sewell AK. Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region. Eur J Immunol 2007; 37: 13231333.
  • 42
    Melenhorst JJ,Scheinberg P,Chattopadhyay PK,Lissina A,Gostick E,Cole DK,Wooldridge L,van den Berg HA,Bornstein E,Hensel NF, Douek DC, Roederer M, Sewell AK, Barrett AJ, Price DA. Detection of low avidity CD8+ T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers. J Immunol Methods 2008; 338: 3139.
  • 43
    Betts MR,Brenchley JM,Price DA,De Rosa SC,Douek DC,Roederer M,Koup RA. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281: 6578.
  • 44
    Ge Q,Stone JD,Thompson MT,Cochran JR,Rushe M,Eisen HN,Chen J,Stern LJ. Soluble peptide-MHC monomers cause activation of CD8+ T cells through transfer of the peptide to T cell MHC molecules. Proc Natl Acad Sci USA 2002; 99: 1372913734.
  • 45
    Schott E,Bertho N,Ge Q,Maurice MM,Ploegh HL. Class I negative CD8 T cells reveal the confounding role of peptide-transfer onto CD8 T cells stimulated with soluble H2-Kb molecules. Proc Natl Acad Sci USA 2002; 99: 1373513740.
  • 46
    Precopio ML,Betts MR,Parrino J,Price DA,Gostick E,Ambrozak DR,Asher TE,Douek DC,Harari A,Pantaleo G, Bailer R, Graham BS, Roederer M, Koup RA. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 2007; 204: 14051416.
  • 47
    Xu XN,Purbhoo MA,Chen N,Mongkolsapaya J,Cox JH,Meier UC,Tafuro S,Dunbar PR,Sewell AK,Hourigan CS, Appay V, Cerundolo V, Burrows SR, McMichael AJ, Screaton GR. A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex. Immunity 2001; 14: 591602.
  • 48
    Cebecauer M,Guillaume P,Hozak P,Mark S,Everett H,Schneider P,Luescher IF. Soluble MHC-peptide complexes induce rapid death of CD8+ CTL. J Immunol 2005; 174: 68096819.
  • 49
    Hutchinson SL,Wooldridge L,Tafuro S,Laugel B,Glick M,Boulter JM,Jakobsen BK,Price DA,Sewell AK. The CD8 T cell coreceptor exhibits disproportionate biological activity at extremely low binding affinities. J Biol Chem 2003; 278: 2428524293.